BACKGROUND: Percutaneous revascularization in diabetic is frequent and the use of drug-eluting stents (DES) is desirable, reducing restenosis and the need for repeat revascularization. The objective of this study was to compare the long-term outcomes of diabetic patients treated with and without DES. METHODS: A consecutive cohort of diabetic patients undergoing percutaneous coronary intervention (PCI) between 01/2009 and 12/2012 in a public tertiary hospital was prospectively followed-up. RESULTS: Nine hundred and thirty-nine diabetic patients (38.3%) treated with DES and 580 (61.7%) treated with bare metal stents (BMS) were evaluated. The rate of major adverse cardiac events (MACE) in 12.6 ± 3.4 months was greater in the BMS group (9.5% vs. 14.8%; RR, 1.56; 95% CI, 1.07-2.27; P = 0.02), as well as death (2.8% vs. 6.7%; RR, 2.41; 95% CI, 1.22-4.77; P < 0.01), and target vessel revascularization (3.9% vs. 7.2%; RR, 1.85; 95% CI, 1.03-3.35; P = 0.04). There were no differences in the incidence of myocardial infarction (1.7% vs. 0.5%; RR, 0.30; 95% CI, 0.07-1.23; P = 0.08) or stroke (1.1% vs. 0.2%; RR, 0.15; 95% CI, 0.01-1.37; P = 0.07). Multivariate analysis indicated that chronic kidney disease (RR, 2.05; 95% CI, 1.40-2.98; P < 0.01) and acute coronary syndrome (RR, 2.08; 95% CI 1.42-3.02; P < 0.01) were the only independent predictors of MACE. CONCLUSIONS: In non-selected diabetic patients the long-term clinical outcome was worse for patients treated with BMS. After adjusting for confounding variables, the use of DES was not an independent predictor of reduced MACE.
Percutaneous coronary intervention; Diabetes mellitus; Drug-eluting stents; Coronary artery disease
